Mga Batayang Estadistika
| CIK | 1680367 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Shattuck Labs, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 26, 2025 |
EX-99.1 Exhibit 99.1 Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors – Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents, assuming full exercise o |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39593 81-2575858 (State or other jurisdiction of incorporation or organization) |
|
| August 14, 2025 |
Exhibit 99.1 Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights –Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2025 – – Cash balance of approximately $50.5 million at end |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Shattuck Labs, Inc. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| August 5, 2025 |
Form of Registration Rights Agreement EX-10.2 Exhibit 10.2 Final Form REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [•], 2025, is entered into by and among Shattuck Labs, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39593 81-2575858 (State or other jurisdiction of incorporation or organization) |
|
| August 5, 2025 |
EX-4.2 Exhibit 4.2 Final Form THIS WARRANT AND THE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED |
|
| August 5, 2025 |
EX-99.1 Exhibit 99.1 Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million – Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate proceeds anticipated to fund operations into 2029 – |
|
| August 5, 2025 |
EX-4.1 Exhibit 4.1 Final Form THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SE |
|
| August 5, 2025 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 4, 2025, by and among Shattuck Labs, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are exec |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 Shattuck Labs, Inc. |
|
| May 21, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| May 1, 2025 |
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights –Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – –Cash balance of approximately $60. |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 Shattuck Labs, Inc. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| March 27, 2025 |
As filed with the Securities and Exchange Commission on March 27, 2025 As filed with the Securities and Exchange Commission on March 27, 2025 Registration No. |
|
| March 27, 2025 |
Master Services Agreement, dated November 18, 2024, by and between S [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 27, 2025 |
Exhibit 99.1 Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights –Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable saf |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Shattuck Labs, Inc. |
|
| March 27, 2025 |
Non-Employee Director Compensation Policy, as Amended NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Shattuck Labs, Inc. |
|
| March 27, 2025 |
Up to $24,474,604 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-263553 AMENDMENT NO. 1 To Prospectus Supplement dated July 29, 2022 (To Prospectus dated July 29, 2022) Up to $24,474,604 Common Stock This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends and supplements the information in the prospectus, dated July 29, 2022, filed as part of our registration statement on Form S-3 (File No. 3 |
|
| March 27, 2025 |
Shattuck Labs, Inc. INSIDER TRADING POLICY (Revised October 18, 2024) I.INTRODUCTION Federal and state laws prohibit buying, selling, gifting or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such material nonpublic information (“MNPI”) from disclosing this information to ot |
|
| March 27, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) Shattuck Labs, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| December 6, 2024 |
STTK / Shattuck Labs, Inc. / Redmile Group, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2430374d1sc13da.htm SC 13D/A UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Shattuck Labs, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82024L103 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-30 |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Shattuck Labs, Inc. |
|
| November 14, 2024 |
Exhibit 99.1 Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights –Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – –Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, November 14, 2024 – Shattuck Labs |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| November 13, 2024 |
STTK / Shattuck Labs, Inc. / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d816256dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* SHATTUCK LABS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82024L103 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Che |
|
| October 1, 2024 |
Exhibit 99.1 Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival comp |
|
| October 1, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Shattuck Labs, Inc. |
|
| August 16, 2024 |
STTK / Shattuck Labs, Inc. / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SHATTUCK LABS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82024L103 (CUSIP Number) August 14, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| August 1, 2024 |
Exhibit 99.1 Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights –Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients at the European Society of Hematol |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Shattuck Labs, Inc. |
|
| June 14, 2024 |
Exhibit 99.1 Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initia |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Shattuck Labs, Inc. |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 Shattuck Labs, Inc. |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 Shattuck Labs, Inc. |
|
| May 2, 2024 |
Exhibit 99.1 Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights –Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – –Randomized, controlled Phase |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Shattuck Labs, Inc. |
|
| May 2, 2024 |
Execution Copy Collaboration and License Agreement COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (this “Agreement”), effective this thirteenth day of February, 2024 (the “Effective Date”), is between Ono Pharmaceutical Co. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| April 23, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 Shattuck Labs, Inc. |
|
| March 4, 2024 |
Exhibit 99.1 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors AUSTIN, TX & DURHAM, NC, March 4, 2024 – Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmun |
|
| February 29, 2024 |
Form of Stock Option Grant Notice and Stock Option Agreement SHATTUCK LABS, INC. 2020 EQUITY INCENTIVE PLAN NOTICE OF GRANT OF STOCK OPTIONS Notice of Grant Shattuck Labs, Inc. (the “Company”) hereby grants to the Optionee named below the option to purchase shares (the “Option Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) upon the terms and subject to the conditions set forth in this Grant Notice, the Shattuck Labs |
|
| February 29, 2024 |
SHATTUCK LABS, INC. 2020 EQUITY INCENTIVE PLAN NOTICE OF GRANT OF STOCK OPTIONS Notice of Grant Shattuck Labs, Inc. (the “Company”) hereby grants to the Optionee named below the option to purchase shares (the “Option Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) upon the terms and subject to the conditions set forth in this Grant Notice, the Shattuck Labs |
|
| February 29, 2024 |
Exhibit 99.1 Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights –Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on |
|
| February 29, 2024 |
Incentive Compensation Clawback Policy Shattuck Labs, Inc. RULE 10D-1 CLAWBACK POLICY Recoupment of Incentive-Based Compensation It is the policy of Shattuck Labs, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements (including any such correction that is material to the previously issued financial statements, or that would result in a material missta |
|
| February 29, 2024 |
Non-Employee Director Compensation Policy NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Shattuck Labs, Inc. |
|
| February 29, 2024 |
Power of Attorney (included on signature page hereto). As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) Shattuck Labs, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Shattuck Labs, Inc. |
|
| February 29, 2024 |
by and between Shattuck Labs, Inc. and EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of June 1, 2021 (the “Effective Date”), by and between Shattuck Labs, Inc. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| February 29, 2024 |
SHATTUCK LABS, INC. 2020 EQUITY INCENTIVE PLAN NOTICE OF GRANT OF AWARD OF RESTRICTED STOCK UNITS Notice of Grant Shattuck Labs, Inc. (the “Company”) hereby grants to the Participant named below the number of restricted stock units specified below (the “Award”). Each restricted stock unit represents the right to receive one share of the Company’s common stock, par value $0.0001 per share (the “Com |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2024 Shattuck Labs, Inc. |
|
| February 2, 2024 |
Prospectus 3,100,823 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276677 Prospectus 3,100,823 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 3,100,823 shares (the “Shares”) of common stock, par value $0.0001 per share, of Shattuck Labs, Inc. (“Shattuck,” “we,” “our” or |
|
| January 30, 2024 |
Shattuck Labs, Inc. 500 W. 5th Street, Suite 1200 Austin, TX 78701 Shattuck Labs, Inc. 500 W. 5th Street, Suite 1200 Austin, TX 78701 January 30, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Shattuck Labs, Inc. Registration Statement on Form S-3 (File No. 333-276677) To Whom it May Concern: Pursuant to Rule 461 under the Securities Act of 1933, as amended (t |
|
| January 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Shattuck Labs, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82024L103 (CUSIP Number) January 17, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 24, 2024 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables FORM S-3 (Form Type) Shattuck Labs, Inc. |
|
| January 24, 2024 |
As filed with the Securities and Exchange Commission on January 24, 2024. Table of Contents As filed with the Securities and Exchange Commission on January 24, 2024. |
|
| January 2, 2024 |
JOINT FILING AGREEMENT December 29, 2023 EX-99.1 2 d535790dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT December 29, 2023 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule o |
|
| January 2, 2024 |
STTK / Shattuck Labs, Inc. / Prosight Management, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SHATTUCK LABS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82024L103 (CUSIP Number) December 21, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| December 26, 2023 |
STTK / Shattuck Labs, Inc. / Redmile Group, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2333671d1sc13da.htm SC 13D/A UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Shattuck Labs, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82024L103 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-30 |
|
| December 22, 2023 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of December 21, 2023, by and among Shattuck Labs, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securiti |
|
| December 22, 2023 |
Exhibit 1.1 Shattuck Labs, Inc. 4,651,163 Shares of Common Stock ($0.0001 par value) Underwriting Agreement New York, New York December 21, 2023 Evercore Group L.L.C. As Representative of the several Underwriters, c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Ladies and Gentlemen: Shattuck Labs, Inc., a Delaware corporation (the “Company”), proposes to sell to the several |
|
| December 22, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 21, 2023, by and among SHATTUCK LABS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Shattuck Labs, Inc. |
|
| December 22, 2023 |
EX-4.1 Exhibit 4.1 THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRAT |
|
| December 22, 2023 |
4,651,163 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263553 Prospectus Supplement (To Prospectus dated July 29, 2022) 4,651,163 Shares of Common Stock We are offering 4,651,163 shares of our common stock, par value $0.0001 per share pursuant to this prospectus supplement and the accompanying prospectus. The public offering price for each share of common stock is $6.45. Our |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Shattuck Labs, Inc. |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 Shattuck Labs, Inc. |
|
| December 13, 2023 |
Exhibit 99.1 Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients – Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete res |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| November 9, 2023 |
Exhibit 99.1 Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights –Positive interim data from Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC) demonstrated an acceptable safety profile and encouraging anti-tumor activity that compares favorably to PLD as a monotherapy; exp |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Shattuck Labs, Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| August 10, 2023 |
Exhibit 99.1 Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights –Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting, including data supporting 3 mg/kg as the appropriate dose for each PROC combination cohort – –Com |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Shattuck Labs, Inc. |
|
| May 24, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Shattuck Labs, Inc. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Shattuck Labs, Inc. |
|
| May 9, 2023 |
Exhibit 99.1 Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights –Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in June – –Dosed first patients in Phase 1B clinical trial of SL-172154 in combination with m |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| April 6, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 6, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Shattuck Labs, Inc. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Shattuck Labs, Inc. |
|
| February 23, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) Shattuck Labs, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| February 23, 2023 |
Exhibit 99.1 Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates –Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer – –Dosed patients in first combination cohort with azacitidine in ongoing Phase 1A/B clinical trial of SL-172154 in acute myeloid leukemia |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Agreement dated February 4, 2022 by and between Shattuck La Exhibit 10.25 CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of February 4, 2022 (the “Effective Date”), is by and between Shattuck Labs, Inc., a Delaware corporation (“Shattuck”), with a place of business at 500 W. 5th Street, Suite 1200, Austin, Texas 78701 (“Shattuck”) and ImmunoGen, Inc., having a place of bu |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Shattuck Labs, Inc. |
|
| November 8, 2022 |
Exhibit 99.1 Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights ?Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 ? ?Dosed first patient in ongoing Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resist |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Shattuck Labs, Inc. |
|
| August 11, 2022 |
Exhibit 99.1 Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights ?Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3?2022 with initial combination data expected in 1H?2023 ? ?Dose escalation ongoing for Phase 1 clinical trial of SL-172154 in acute myeloid le |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| July 29, 2022 |
Up to $75,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263553 PROSPECTUS SUPPLEMENT (To Prospectus dated July 29, 2022) Up to $75,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with SVB Securities LLC, or SVB Securities, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement and the accompany |
|
| July 29, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 Shattuck Labs, Inc. |
|
| July 29, 2022 |
Exhibit 1.1 SHATTUCK LABS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT July 29, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Shattuck Labs, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Securities LLC (the ?Agent?), as follows: 1. Issuance and Sale of S |
|
| July 28, 2022 |
As filed with the Securities and Exchange Commission on July 28, 2022. S-3/A 1 d386806ds3a.htm S-3/A As filed with the Securities and Exchange Commission on July 28, 2022. Registration No. 333-263553 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 81-2575858 (State or other |
|
| July 28, 2022 |
July 28, 2022 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Shattuck Labs, Inc. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Shattuck Labs, Inc. |
|
| May 12, 2022 |
Exhibit 99.1 Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights ?Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on track to begin in 2H?2022; full dose-escalation data in monotherapy and initial data in combination both expected in 1H?2023 ? ?Dose escalation ong |
|
| April 21, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| March 15, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on March 15, 2022. |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| March 15, 2022 |
Exhibit 4.3 SHATTUCK LABS, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314(a) 4 |
|
| March 15, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) Shattuck Labs, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Shattuck Labs, Inc. |
|
| March 15, 2022 |
Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 10-K of Shattuck Labs, Inc. (the “Company”) for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company here |
|
| March 15, 2022 |
Exhibit 99.1 Shattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights ? Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer patients ? ? Presented positive initial dose-escalation clinical data for SL-279252, i |
|
| March 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Shattuck Labs, Inc. |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| February 14, 2022 |
STTK / Shattuck Labs Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Shattuck Labs, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82024L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| January 14, 2022 |
Exhibit 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Shattuck Labs, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the under |
|
| January 14, 2022 |
STTK / Shattuck Labs Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SHATTUCK LABS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82024L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 14, 2022 |
Exhibit 99.3 POWER OF ATTORNEY Know all by these present, that Millennium Pharmaceuticals, Inc. (the ?Reporting Person?) hereby constitutes and appoints Paul Sundberg as the Reporting Person?s true and lawful attorney-in-fact to: 1)prepare, execute in the Reporting Person?s name and on the Reporting Person?s behalf, and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form ID, i |
|
| January 14, 2022 |
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Millennium Pharmaceuticals, Inc. is the direct beneficial owner of 2,090,858 shares of Common Stock of Shattuck Labs, Inc. Millennium Pharmaceuticals, Inc. is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharma |
|
| November 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Shattuck Labs, Inc. |
|
| November 15, 2021 |
SITC 2021 Investor Conference Call & Webcast NASDAQ: STTK November 12, 2021 Forward-Looking Statements 2 This presentation contains ?forward-looking statements? within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on our estimates and assumptions. |
|
| November 9, 2021 |
Exhibit 10.1 TERMINATION AGREEMENT This Termination Agreement (this ?Agreement?), dated as of November 8, 2021 (the ?Effective Date?), is entered into by and between Millennium Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (?Millennium?), and Shattuck Labs, Inc., a Delaware corporation having its principal place of |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| November 9, 2021 |
Exhibit 99.1 Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights ? Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting; both clinical trials remain ongoing ? ? SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose- |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Shattuck Labs, Inc. |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 Shattuck Labs, Inc. |
|
| October 28, 2021 |
Exhibit 99.1 Shattuck Labs Announces Changes to its Board of Directors ? Shattuck Labs appoints new Board member, Dr. Carrie Brownstein, M.D.; Dr. George Golumbeski, Ph.D., appointed as Chairman of the Board ? AUSTIN, TX and DURHAM, NC, October 28, 2021 ? Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion protein |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| August 11, 2021 |
Exhibit 99.1 Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252 ? Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 Shattuck Labs, Inc. |
|
| June 10, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 Shattuck Labs, Inc. |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Shattuck Labs, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82024L103 (CUSIP Number) May 6, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Shattuck Labs, Inc. |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| May 10, 2021 |
Exhibit 99.1 Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights ? Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRP?-Fc-CD40L), expected in the second half of 2021 ? ? IND filings for SL-172154 in hematologic malignancies anticipated in the second half of 2021 ? ? Dose-escalation data fro |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 22, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 16, 2021 |
Amendment No. 1 to Employment Agreement, dated March Exhibit 10.14 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 (this ?Amendment?) is entered into as of this 12th day of March, 2021 by and between Shattuck Labs, Inc. (the ?Company?) and Casi DeYoung (?Executive?) and amends that certain Employment Agreement dated as of December 9, 2019, between the Company and Executive. WHEREAS, the Company currently employs Executive pursuant to th |
|
| March 16, 2021 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a summary of the material terms of our capital stock, as well as other material terms of our second amended and restated certificate of incorporation and amended bylaws and certain provisions of Delaware law. This summary does not purport to be comple |
|
| March 16, 2021 |
Amendment No. 1 to Employment Agreement, dated March Exhibit 10.10 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 (this ?Amendment?) is entered into as of this 12th day of March, 2021 by and between Shattuck Labs, Inc. (the ?Company?) and Erin Ator Thomson (?Executive?) and amends that certain Employment Agreement dated as of December 5, 2019 (the ?Agreement?) between the Company and Executive. WHEREAS, the Company currently employs Ex |
|
| March 16, 2021 |
Amendment No. 1 to Employment Agreement, dated March Exhibit 10.8 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 (this ?Amendment?) is entered into as of this 12th day of March, 2021 by and between Shattuck Labs, Inc. (the ?Company?) and Arundathy Nirmalini Pandite (?Executive?) and amends that certain Employment Agreement dated as of December 5, 2019, between the Company and Executive. WHEREAS, the Company currently employs Executive |
|
| March 16, 2021 |
Amendment No. 1 to Employment Agreement, dated March Exhibit 10.12 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 (this ?Amendment?) is entered into as of this 12th day of March, 2021 by and between Shattuck Labs, Inc. (the ?Company?) and Andrew Neill (?Executive?) and amends that certain Employment Agreement dated as of December 5, 2019, between the Company and Executive. WHEREAS, the Company currently employs Executive pursuant to th |
|
| March 16, 2021 |
Amendment No. 2 to Employment Agreement, dated March Exhibit 10.6 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 2 (this ?Amendment?) is entered into as of this 12th day of March, 2021 by and between Shattuck Labs, Inc. (the ?Company?) and Taylor Schreiber (?Executive?) and amends that certain Employment Agreement dated as of December 5, 2019, as previously amended on March 27, 2020 (the ?Agreement?) between the Company and Executive. WH |
|
| March 16, 2021 |
Employment Agreement, dated December 9, 2019, by and between Shattuck Labs, Inc. and Casi DeYoung. Exhibit 10.13 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of December 9, 2019 (the ?Effective Date?), by and between Shattuck Labs, Inc. (the ?Company?) and Casi DeYoung (?Executive?). WHEREAS, the Company wishes to employ Executive as the Chief Business Officer of the Company and Executive wishes to work as the Chief Business Officer of the Company; and WHE |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| March 16, 2021 |
Exhibit 10.21 * * * * * * * * * * * * * * * * * * * * Office Lease 500 West 5th Street Austin, Texas * * * * * * * * * * * * * * * * * * * * Between Shattuck Labs, Inc. (Tenant) and International Bank of Commerce, Laredo, Texas (Landlord) Suite 1200, IBC Bank Plaza With an Effective Date of January 8th 2021 {W1007584.6} 3641172.v9 TABLE OF CONTENTS Page KEY TERMS SCHEDULE 1. PROJECT 1 2. LEASED PR |
|
| March 16, 2021 |
As filed with the Securities and Exchange Commission on March 16, 2021 Registration No. |
|
| March 15, 2021 |
Exhibit 99.1 Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights ? Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRP?-Fc-CD40L), expected in the second half of 2021 ? ? Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 ( |
|
| March 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 Shattuck Labs, Inc. |
|
| January 29, 2021 |
Exhibit 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Shattuck Labs, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the under |
|
| January 29, 2021 |
Exhibit 99.3 POWER OF ATTORNEY Know all by these present, that Millennium Pharmaceuticals, Inc. (the “Reporting Person”) hereby constitutes and appoints Paul Sundberg as the Reporting Person’s true and lawful attorney-in-fact to: 1)prepare, execute in the Reporting Person’s name and on the Reporting Person’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, i |
|
| January 29, 2021 |
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Millennium Pharmaceuticals, Inc. is the direct beneficial owner of 2,100,312 shares of Common Stock of Shattuck Labs, Inc. Millennium Pharmaceuticals, Inc. is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharma |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SHATTUCK LABS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82024L103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. |
|
| November 13, 2020 |
Exhibit 99.1 Shattuck Labs Reports Third Quarter 2020 Financial Results and Recent Business Highlights – Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer – – Completed initial public offering in October 2020 raising approximately $232.3 million in gross proceeds and extending cash runway through 2024 – |
|
| November 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2020 Shattuck Labs, Inc. |
|
| October 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Shattuck Labs, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 820824L103 (CUSIP Number) Erin Ator Thomson General Counsel Shattuck Labs, Inc. 1018 W. 11th Street, Suite 100 Austin, TX 78073 (919) 864-2700 (Name, Address and T |
|
| October 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Shattuck Labs, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 820824L103 (CUSIP Number) Erin Ator Thomson General Counsel Shattuck Labs, Inc. 1018 W. 11th Street, Suite 100 Austin, TX 78073 (919) 864-2700 (Name, Address and T |
|
| October 19, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 19, 2020 Registration No. |
|
| October 15, 2020 |
EX-99.1 2 tm2033274d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the “Schedule 13D”) relating to the common stock, $0.0001 |
|
| October 15, 2020 |
UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Shattuck Labs, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82024L103 (CUSIP Number) Redmile Group, LLC Jeremy C. Green One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 Attention: Legal Depart |
|
| October 14, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SHATTUCK LABS, INC. (a Delaware corporation) Shattuck Labs, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Shattuck Labs, Inc. The date of the filing of its original Certificate of Incorporation with the Secr |
|
| October 14, 2020 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2020 Shattuck Labs, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39593 81-2575858 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 14, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SHATTUCK LABS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Shattuck Labs, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records |
|
| October 13, 2020 |
11,882,352 Shares Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-248918 and 333-249393 PROSPECTUS 11,882,352 Shares Common Stock This is the initial public offering of our shares of common stock. We are selling 11,882,352 shares of our common stock. The initial public offering price is $17.00 per share of common stock. Prior to this offering, no public market for our common stock exi |
|
| October 8, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on October 8, 2020 Registration No. |
|
| October 8, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on October 7, 2020 Registration No. |
|
| October 7, 2020 |
October 7, 2020 CONFIDENTIAL SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell and Tim Buchmiller Re: Shattuck Labs, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed October 5, 2020 File No. 333-248918 Ladies and Gentlemen: On behalf of Shattuck Labs, Inc |
|
| October 6, 2020 |
CORRESP October 6, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 6, 2020 |
CORRESP October 6, 2020 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 5, 2020 |
October 5, 2020 CONFIDENTIAL SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell and Tim Buchmiller Re: Shattuck Labs, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted September 10, 2020 CIK No. 0001680367 and Shattuck Labs, Inc. Registration Stat |
|
| October 5, 2020 |
EX-4.1 Exhibit 4.1 ST INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 82024L 10 3 SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF Shattuck Labs, Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this C |
|
| October 5, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Shattuck Labs, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-2575858 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 1018 W. 11th St |
|
| October 5, 2020 |
EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SHATTUCK LABS, INC. (a Delaware corporation) Shattuck Labs, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Shattuck Labs, Inc. The date of the filing of its original Certificate of Incorporation with t |
|
| October 5, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on October 5, 2020 Registration No. |
|
| October 5, 2020 |
EX-3.1 Exhibit 3.1 SHATTUCK LABS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Shattuck Labs, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. |
|
| October 5, 2020 |
EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF SHATTUCK LABS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Shattuck Labs, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records |
|
| October 5, 2020 |
EX-10.10 Exhibit 10.10 SHATTUCK LABS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN Section 1. PURPOSE The purpose of this Employee Stock Purchase Plan (the “Plan”) is to provide an opportunity for Employees of Shattuck Labs, Inc., a Delaware corporation (“Sponsor”) and its Participating Subsidiaries (collectively Sponsor and its Participating Subsidiaries shall be referred to as the “Company”), to purch |
|
| October 5, 2020 |
EX-10.1 Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is entered into as of by and between Shattuck Labs, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company. RECITALS WHEREAS, the Board of Director |
|
| October 5, 2020 |
EX-10.11 Exhibit 10.11 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Shattuck Labs, Inc. (the “Company”), is to provide a compensation package that enables the Company to attract and retain high-caliber directors and aligns their interests with the interests of the Company’s stockholders. 1. Eligibility The Policy applies |
|
| October 5, 2020 |
EX-10.9 Exhibit 10.9 SHATTUCK LABS, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD: SEPTEMBER 29, 2020 1. GENERAL. (a) Successor to Prior Plan. This Plan is the successor to the Shattuck Labs, Inc. 2016 Stock Incentive Plan, as amended by Amendment No. 1 thereto (the “Prior Plan”). From and after 12:01 a.m. Central time on the Effective Date, no additional stock awards will be granted under |
|
| September 25, 2020 |
CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND PROVIDED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. |
|
| September 18, 2020 |
EX-10.4 Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Taylor Schreiber (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the Chief Scientific Officer of the Company and Executive wishes to continue to work as the Chief Sci |
|
| September 18, 2020 |
EX-10.12 Exhibit 10.12 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version EXCLUSIVE LICENSE AGREEMENT By and between Shattuck Labs, Inc. and Heat Biologics, Inc. Effective as of June 3, 2016 i [***] = CERTAIN CONFIDENTIA |
|
| September 18, 2020 |
EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF SHATTUCK LABS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Shattuck Labs, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records |
|
| September 18, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on September 18, 2020 Registration No. |
|
| September 18, 2020 |
EX-4.2 Exhibit 4.2 SHATTUCK LABS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This Second Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of June 12, 2020 by and among Shattuck Labs, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as a |
|
| September 18, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 Shattuck Labs, Inc. [•] Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York [•], 2020 Citigroup Global Markets Inc. Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New |
|
| September 18, 2020 |
EX-10.14 Exhibit 10.14 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Master Services Agreement This Master Services Agreement (this “Agreement”) dated March 31, 2017 (the “Effective Date”), between Shattuck Labs, Inc., having a place |
|
| September 18, 2020 |
EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SHATTUCK LABS, INC. (a Delaware corporation) Shattuck Labs, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Shattuck Labs, Inc. The date of the filing of its original Certificate of Incorporation with t |
|
| September 18, 2020 |
EX-10.13 Exhibit 10.13 LEASE AGREEMENT BETWEEN PARMER RTP, LLC, AS LANDLORD, AND SHATTUCK LABS, INC., AS TENANT DATED APRIL 17, 2018 DURHAM, NORTH CAROLINA BASIC LEASE INFORMATION Lease Date: April 17, 2018 Landlord: PARMER RTP, LLC, a Delaware limited liability company Tenant: SHATTUCK LABS, INC., a Delaware corporation Premises: Suite No. 200, containing approximately 13,523 rentable square feet |
|
| September 18, 2020 |
Amended and Restated Certificate of Incorporation of the registrant, as currently in effect. EX-3.1 Exhibit 3.1 SHATTUCK LABS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Shattuck Labs, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. |
|
| September 18, 2020 |
Bylaws of the registrant, as currently in effect. EX-3.3 Exhibit 3.3 BYLAWS OF SHATTUCK LABS, INC. ARTICLE I OFFICES 1.1 Registered Office. The initial registered office of Shattuck Labs, Inc. (the “Corporation”) in the State of Delaware shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “Certificate of Incorporation”), and may be changed from time to time in the discretion of the B |
|
| September 18, 2020 |
EX-10.5 Exhibit 10.5 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 (the “Amendment”) is entered into as of this 27th day of March, 2020 by and between Shattuck Labs, Inc. (the “Company”) and Taylor Schreiber (the “Executive”) and amends that certain Employment Agreement dated as of December 5, 2019 (the “Agreement”) between the Company and the Executive. WHEREAS, the Company current |
|
| September 18, 2020 |
EX-10.7 Exhibit 10.7 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Erin Ator Thomson (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the General Counsel of the Company and Executive wishes to continue to work as the General Counsel o |
|
| September 18, 2020 |
EX-10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Josiah C. Hornblower (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the Chief Executive Officer of the Company and Executive wishes to continue to work as the Chief |
|
| September 18, 2020 |
EX-10.8 Exhibit 10.8 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Andrew Neill (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the Vice President of Corporate Development and Strategy of the Company and Executive wishes to continue |
|
| September 18, 2020 |
EX-10.6 Exhibit 10.6 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Arundathy Nirmalini Pandite (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the Chief Medical Officer of the Company and Executive wishes to continue to work as the C |
|
| September 18, 2020 |
EX-10.3 Exhibit 10.3 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 (the “Amendment”) is entered into as of this 27th day of March, 2020 by and between Shattuck Labs, Inc. (the “Company”) and Josiah C. Hornblower (the “Executive”) and amends that certain Employment Agreement dated as of December 5, 2019 (the “Agreement”) between the Company and the Executive. WHEREAS, the Company cur |
|
| September 18, 2020 |
EX-10.11 Exhibit 10.11 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version SHATTUCK LABS, INC. and MILLENNIUM PHARMACEUTICALS, INC. COLLABORATION AGREEMENT Effective as of August 8, 2017 [***] = CERTAIN CONFIDENTIAL INFOR |
|
| September 10, 2020 |
DRSLTR September 10, 2020 CONFIDENTIAL SUBMISSION VIA EDGAR AND HAND DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell and Tim Buchmiller Re: Shattuck Labs, Inc. Draft Registration Statement on Form S-1 Submitted August 7, 2020 Amendment No. 1 to Draft Registration Statement on Form |
|
| September 10, 2020 |
EX-10.6 Exhibit 10.6 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Arundathy Nirmalini Pandite (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the Chief Medical Officer of the Company and Executive wishes to continue to work as the C |
|
| September 10, 2020 |
EX-3.1 Exhibit 3.1 SHATTUCK LABS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Shattuck Labs, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. |
|
| September 10, 2020 |
BYLAWS OF SHATTUCK LABS, INC. ARTICLE I EX-3.3 Exhibit 3.3 BYLAWS OF SHATTUCK LABS, INC. ARTICLE I OFFICES 1.1 Registered Office. The initial registered office of Shattuck Labs, Inc. (the “Corporation”) in the State of Delaware shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “Certificate of Incorporation”), and may be changed from time to time in the discretion of the B |
|
| September 10, 2020 |
DRS/A Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 10, 2020 This Amendment No. |
|
| September 10, 2020 |
EX-10.7 Exhibit 10.7 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Erin Ator Thomson (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the General Counsel of the Company and Executive wishes to continue to work as the General Counsel o |
|
| September 10, 2020 |
EX-10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Josiah C. Hornblower (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the Chief Executive Officer of the Company and Executive wishes to continue to work as the Chief |
|
| September 10, 2020 |
EX-10.4 Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Taylor Schreiber (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the Chief Scientific Officer of the Company and Executive wishes to continue to work as the Chief Sci |
|
| September 10, 2020 |
EX-10.8 Exhibit 10.8 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Andrew Neill (“Executive”). WHEREAS, the Company wishes to continue to employ Executive as the Vice President of Corporate Development and Strategy of the Company and Executive wishes to continue |
|
| August 7, 2020 |
DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 7, 2020 Registration No. |
